Dna
Vendor:
First CVE: Feb 16, 2022 · Active for 4 years
2
Total CVEs
More Total CVEs than 49% of tracked products
1.0
Avg CVEs / Year
Bottom 1%
8.2
Avg CVSS
Higher Avg CVSS than 72% of tracked products
0.0%
KEV Rate
Bottom 1%
Trends Over Time
The number and severity of CVEs published that impact Dna over time
Volume of CVEsAvg CVSS Base Score
First CVE
Feb 16, 2022
4 years ago
Most Recent CVE
Feb 12, 2026
165 days ago
CVE Severity & Scoring
Dna2 CVEs
100%
All CVEs352,727 CVEs
45%
40%
11%
High
Attack Vector
Local0 (0.0%)
Network1 (50.0%)
Unknown0 (0.0%)
Physical0 (0.0%)
Adjacent Network1 (50.0%)
Attack Complexity
Low2 (100.0%)
High0 (0.0%)
Unknown0 (0.0%)
User Interaction
None2 (100.0%)
Unknown0 (0.0%)
Required0 (0.0%)
Privileges Required
Low0 (0.0%)
High0 (0.0%)
None2 (100.0%)
Unknown0 (0.0%)
Top CVEs
Signals from CVEs in this product scope (2 CVEs).
2 CVEs · Highest risk first
| CVE | Published | CVSS | Risk | KEV | Exploit |
|---|---|---|---|---|---|
CVE-2021-26726HIGH A remote code execution vulnerability affecting a Valmet DNA service listening on TCP port 1517, allows an attacker to execute commands with SYSTEM privileges This issue affects: V | Feb 16, 2022 | 8.8 | 27 | NO | NO |
CVE-2025-15577HIGH An unauthenticated attacker can exploit this vulnerability by manipulating URL to achieve arbitrary file read access.This issue affects Valmet DNA Web Tools: C2022 and older. | Feb 12, 2026 | 7.5 | 24 | NO | NO |
Exploit Exposure
Signals from CVEs in this product scope (2 CVEs).
CISA KEV
0 CVEs
0.0% of CVEs· Bottom 1%
Metasploit
0 CVEs
0.0% of CVEs· Bottom 1%
Nuclei
0 CVEs
0.0% of CVEs· Bottom 1%
ExploitDB
0 CVEs
0.0% of CVEs· Bottom 1%
Social Chatter
Signals from CVEs in this product scope (2 CVEs).
Media Mentions
Signals from CVEs in this product scope (2 CVEs).
Top CNAs Publishing CVEs For Dna
Top CWEs
Versions
No cataloged versions.